96 -4 (32/3) 2020 — Nazirova Z.M., Asrankulova D.B. — GENETIC POLYMORPHISM OF ESTROGEN METABOLISM ENZYMES IN WOMEN WITH HYPERPLASTIC PROCESSES ENDOMETRY IN PERIMENOPAUSE
GENETIC POLYMORPHISM OF ESTROGEN METABOLISM ENZYMES IN WOMEN WITH HYPERPLASTIC PROCESSES ENDOMETRY IN PERIMENOPAUSE
Nazirova Z.M, -Andijan State Medical Institute
Asrankulova D.B. -Andijan State Medical Institute
Resume
Numerous studies have shown that estrogens in most cases play an important role in the development of uterine fibroids, hyperplastic processes and endometrial cancer [2,7]. At the same time, the pathogenetic aspects of the combined pathology of the endometrium and myometrium, in particular endometrial hyperplasia and endometrial cancer against the background of uterine fibroids, remain practically unexplored [4]. In the endometrium and myometrium, estrogens are synthesized from androgens by the action of the aromatase enzyme.
Estrogens released from the blood and synthesized in the endometrium bind to the estrogen receptors present in the tissues and stimulate the proliferation of the endometrium, triggering the promoter type of hormonal carcinogenesis. In the genotoxic type of hormonal carcinogenesis, estrogens with the participation of 2- and 4-estrogen hydroxylases are converted into catechol estrogens.
Key words: gesterogen, hyperplasia, endometrium, enzyme, gene.
First page
387
Last page
388
For citation: Nazirova Z.M., Asrankulova D.B., Genetic polymorphism of estrogen metabolism enzymes in women with hyperplastic processes endometry in perimenopause//New Day in Medicine 4(32)2020 387-388 https://cutt.ly/gzMim20
List of References
- Бассалык Л.С., Герштепн Е.С., Куштнскип Н.Е. и др. Определение рецепторов стероидных гормонов в гормонозависимых опухолях для назначения эндокринной терапии: Методические рекомендации. М, 2017. 16 с.
- Берштейн Л.М. Гормональный канцерогенез. СПб., 2010. 199 с.
- Берштейн Л.М., Чернобровкина А.Е., Гамаюнова В.Б. и др. II Вопросы онкологии. 2013. Т. 49, № 1. С. 55 – 59.
- Гаерилов А.С., Мерекина Л.И., Семенов СВ. II Сибир ский мед. журнал. 2012. № 4. С. 34 – 36.
- Ларионов А.А. Конверсия андростендиона в опухолевой и эк- страгонадных тканях и ее связь с гормонально-мета боличес- кими факторами у больных раком молочной железы: /Автореф… дис. канд. мед. наук. СПб., 2007.
- Руководство по эндокринной гинекологии / Под ред. Е.М. Вихляевой. М.: МИА, 2010. 550 с.
- Adamski J., Hohls Е. Jungblut P. II Exp. Clin. Endocrinol. 2014. Vol. 102, № 5. p. 388 – 393.
- Bulun S.E., Economos K., Miller?>, Simpson E.R. II J. Clin. Endocrinol. Metab.2014. Vol. 79, № 6. P.18311 – 18314.
- Cavalieri E.L., Rogan EC, Chakravarti D. II Cell. Mol. Life Sci. 2012. Vol. 59. P. 665 – 81.
- Hukkanen J., Mantyla M., Kangas L. II Pharmacol. Toxicol. 2008. Vol. 82, № 2. P.93 – 97.
- Kennedy J.A. II Naunyn Schmiedebergs Arch. Pharmacol. 2014. Vol. 333, № 4. P. 368 – 376.
- Theron CM, Russel V.A., TaljardJ.J. II J. Steroid Biochem. 2006. Vol. 25, № 4. P. 585 – 591.
- Watanabe K., Sasano Я, Harada N. et al. II Am. Pathol. 2015. Vol. 146. P.491 – 500. 23. Zurcher G., Da Prada M. II J. of Neurochemistry. 2012. Vol. 38, № 1. P. 191 – 195